Lilly (LLY.US) recommends Elpida peptide as a weight loss drug by the UK regulatory agency.
The UK's National Institute for Health and Care Excellence has officially recommended the GLP-1 drug Tirzepatide from Lilly as a weight loss medication.
The UK's drug cost-effectiveness watchdog, the National Institute for Health and Care Excellence (NICE), has formally recommended Eli Lilly and Company's GLP-1 drug Tirzepatide as a weight loss medication. The drug is sold under the names Zepbound for weight loss and Moujaro for treating type 2 diabetes.
Due to anticipated high demand, NICE had earlier stated in December that Tirzepatide would be rolled out over a three-year period, with the "highest clinical need" patients being given priority for the drug.
Related Articles
Under Musk's ownership, SpaceX is aiming to conduct the largest IPO in history, with plans to raise up to $75 billion.
US Stock Market Move | Popular Chinese concept stocks continue to rise, JD.com, Inc. Sponsored ADR Class A (JD.US) up more than 7%
KAISA HEALTH (00876) released its annual performance with a net loss attributable to shareholders of HK$46.678 million, a 0.7% increase year-on-year.
Under Musk's ownership, SpaceX is aiming to conduct the largest IPO in history, with plans to raise up to $75 billion.
US Stock Market Move | Popular Chinese concept stocks continue to rise, JD.com, Inc. Sponsored ADR Class A (JD.US) up more than 7%
KAISA HEALTH (00876) released its annual performance with a net loss attributable to shareholders of HK$46.678 million, a 0.7% increase year-on-year.
